Sigma Planning Corp Trims Position in Edwards Lifesciences Co. (NYSE:EW)

Sigma Planning Corp trimmed its position in Edwards Lifesciences Co. (NYSE:EW) by 23.7% during the 3rd quarter, HoldingsChannel reports. The firm owned 4,132 shares of the medical research company’s stock after selling 1,284 shares during the period. Sigma Planning Corp’s holdings in Edwards Lifesciences were worth $273,000 as of its most recent filing with the SEC.

A number of other large investors have also made changes to their positions in the company. Avantax Advisory Services Inc. increased its holdings in Edwards Lifesciences by 4.1% during the first quarter. Avantax Advisory Services Inc. now owns 6,887 shares of the medical research company’s stock valued at $658,000 after buying an additional 272 shares during the last quarter. M&G Plc purchased a new position in Edwards Lifesciences during the first quarter valued at $853,000. Resurgent Financial Advisors LLC grew its holdings in Edwards Lifesciences by 16.7% during the first quarter. Resurgent Financial Advisors LLC now owns 6,232 shares of the medical research company’s stock valued at $596,000 after purchasing an additional 892 shares during the period. Penobscot Investment Management Company Inc. increased its position in Edwards Lifesciences by 10.0% in the first quarter. Penobscot Investment Management Company Inc. now owns 16,223 shares of the medical research company’s stock worth $1,550,000 after buying an additional 1,480 shares in the last quarter. Finally, Champlain Investment Partners LLC increased its position in Edwards Lifesciences by 3.1% in the first quarter. Champlain Investment Partners LLC now owns 2,964,168 shares of the medical research company’s stock worth $283,256,000 after buying an additional 88,205 shares in the last quarter. 79.46% of the stock is currently owned by institutional investors.

Insiders Place Their Bets

In other Edwards Lifesciences news, insider Larry L. Wood sold 25,000 shares of the company’s stock in a transaction on Tuesday, November 5th. The stock was sold at an average price of $65.91, for a total value of $1,647,750.00. Following the transaction, the insider now owns 198,526 shares of the company’s stock, valued at $13,084,848.66. This represents a 11.18 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, VP Donald E. Bobo, Jr. sold 5,000 shares of Edwards Lifesciences stock in a transaction on Wednesday, September 11th. The stock was sold at an average price of $66.77, for a total value of $333,850.00. Following the sale, the vice president now owns 46,936 shares of the company’s stock, valued at approximately $3,133,916.72. This trade represents a 9.63 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 41,250 shares of company stock valued at $2,744,438 over the last three months. 1.29% of the stock is owned by company insiders.

Wall Street Analyst Weigh In

A number of research analysts recently issued reports on EW shares. Daiwa America downgraded Edwards Lifesciences from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, October 30th. Wells Fargo & Company dropped their price target on shares of Edwards Lifesciences from $90.00 to $80.00 and set an “overweight” rating for the company in a research report on Monday, September 9th. UBS Group decreased their price objective on shares of Edwards Lifesciences from $90.00 to $75.00 and set a “neutral” rating on the stock in a research report on Tuesday, September 10th. JPMorgan Chase & Co. lifted their target price on shares of Edwards Lifesciences from $72.00 to $78.00 and gave the company a “neutral” rating in a research note on Friday, October 25th. Finally, Piper Sandler cut their price target on Edwards Lifesciences from $73.00 to $70.00 and set a “neutral” rating for the company in a research note on Friday, October 25th. Seventeen investment analysts have rated the stock with a hold rating and ten have assigned a buy rating to the stock. Based on data from MarketBeat, Edwards Lifesciences currently has an average rating of “Hold” and an average target price of $75.67.

Edwards Lifesciences Trading Up 2.4 %

EW opened at $67.76 on Friday. The stock has a 50-day moving average of $67.44 and a 200 day moving average of $76.24. The company has a current ratio of 3.46, a quick ratio of 2.89 and a debt-to-equity ratio of 0.06. Edwards Lifesciences Co. has a 12 month low of $58.93 and a 12 month high of $96.12. The firm has a market cap of $39.96 billion, a P/E ratio of 9.78, a P/E/G ratio of 3.74 and a beta of 1.12.

Edwards Lifesciences (NYSE:EW) last announced its earnings results on Thursday, October 24th. The medical research company reported $0.67 EPS for the quarter, hitting analysts’ consensus estimates of $0.67. Edwards Lifesciences had a return on equity of 20.76% and a net margin of 70.82%. The firm had revenue of $1.35 billion during the quarter, compared to analysts’ expectations of $1.57 billion. During the same quarter in the previous year, the business earned $0.59 EPS. The company’s quarterly revenue was up 8.9% on a year-over-year basis. As a group, research analysts forecast that Edwards Lifesciences Co. will post 2.57 EPS for the current year.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.